Sugi Predict

Sugi Predict / Compounds / SCHEMBL4850535

SCHEMBL4850535

SCHEMBL4850535

CCCCCN[C@@H](Cc1ccc(O)cc1)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 1/20 0.51
▸ ACE P12821 3/20 0.50
▸ MME P08473 3/20 0.50
▸ CPA1 P15085 2/20 0.50
▸ ACE2 Q9BYF1 2/20 0.50
▸ GRIA1 P42261 2/20 0.48
▸ NAALAD2 Q9Y3Q0 1/20 0.48
▸ CHRND Q07001 5/20 0.47
▸ CHRNA1 P02708 1/20 0.47
▸ CHRNG P07510 1/20 0.47
▸ CHRNB1 P11230 1/20 0.47
▸ PLG P00747 1/20 0.47
▸ PLAU P00749 1/20 0.47
▸ PRSS1 P07477 1/20 0.47
▸ PRSS2 P07478 1/20 0.47
▸ PRSS3 P35030 1/20 0.47
▸ SIGMAR1 Q99720 1/20 0.46
▸ CA12 O43570 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4850530 1.00 FOLH1 (0.51) FOLH1ACEMMECPA1ACE2
Ammonia Solution, Strong SCHEMBL28124004 0.99 FOLH1 (0.50) FOLH1ACEMMECPA1ACE2
SCHEMBL38651117 0.99 GRIA1 (0.50) FOLH1ACEMMECPA1ACE2
SCHEMBL28031750 0.99 GRIA1 (0.50) FOLH1ACEMMECPA1ACE2
SCHEMBL28663068 0.99 GRIA1 (0.50) FOLH1ACEMMECPA1ACE2
SCHEMBL23778217 0.99 GRIA1 (0.50) FOLH1ACEMMECPA1ACE2
SCHEMBL28379862 0.99 GRIA1 (0.50) FOLH1ACEMMECPA1ACE2
Phosphine SCHEMBL28243264 0.99 FOLH1 (0.50) FOLH1ACEMMECPA1ACE2
SCHEMBL8975007 0.99 GRIA1 (0.50) FOLH1ACEMMECPA1ACE2
SCHEMBL620471 0.99 GRIA1 (0.50) FOLH1ACEMMECPA1ACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110831584-A Targeted drug rescue with novel compositions, combinations and methods thereof 埃克塞瓦有限责任公司 2020-02-21 — — CN claimed
CN-104302772-A Protein for diabetes treatment, protein conjugate and application thereof ADDA BIOTECH INC 2015-01-21 — — CN claimed
US-20060122421-A1 Crystallization of amino acids using ultrasonic agitation BECHTEL SIEGFRIED 2006-06-08 — — US claimed
EP-1461307-A2 CRYSTALLIZATION OF AMINO ACIDS USING ULTRASONIC AGITATION Abbott GmbH & Co. KG (DE) 2004-09-29 — — EP claimed
US-20030166726-A1 Crystallization of amino acids using ultrasonic agitation ABBOTT GMBH & CO. KG (DE) 2003-09-04 — — US claimed
WO-2003057717-A2 CRYSTALLIZATION OF AMINO ACIDS USING ULTRASONIC AGITATION ABBOTT GMBH & CO. KG (DE) 2003-07-17 — — WO claimed
EP-0019115-B1 PANCREOZYMIN-CHOLEZYSTOKININ ACTIVE PEPTIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 1983-01-12 — — EP claimed
CN-110831584-B Targeted drug rescue with novel compositions, combinations and methods thereof 埃克塞瓦有限责任公司 2023-03-10 — — CN disclosed
CN-115209887-A PPAR agonist complexes and methods of use thereof 罗丹菲尔茨有限责任公司 2022-10-18 — — CN disclosed
EP-4028502-A1 N-ACYL-TYROSINE DERIVATIVES AND USES THEREOF SEDERMA (FR) 2022-07-20 — — EP disclosed
CN-114222558-A Methods of inhibiting PAR2 activation and compositions for use in the methods 宝洁公司 2022-03-22 — — CN disclosed
CN-113559105-A Treatment of resistant acne 维奥姆治疗有限公司 2021-10-29 — — CN disclosed
CN-106163526-B Treatment of resistant acne 维奥姆治疗有限公司 2021-07-23 — — CN disclosed
US-5030717-A Binding site which bind to reactant ligand, stabilization SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1991-07-09 — — US disclosed
EP-0260939-A2 Molecules with antibody combining sites that exhibit catalytic properties SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) 1988-03-23 — — EP disclosed
US-4507235-A Method for preparing peptides and intermediate products MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 1985-03-26 — — US disclosed
US-4507235-A Method for preparing peptides and intermediate products MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 1985-03-26 — — US disclosed
US-4368192-A Peptides MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 1983-01-11 — — US disclosed
US-4368192-A Peptides MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 1983-01-11 — — US disclosed
US-4118481-A LYSINE, ARGININE, TYROSINE, PROTEASE INHIBITION BAYER AKTIENGESELLSCHAFT (DE) 1978-10-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166726-A1 Crystallization of amino acids using ultrasonic agitation DNPEP, ANPEP, UBAP2 FOLH1 764/4885ACE 88/4885MME 34/4885
US-20060122421-A1 Crystallization of amino acids using ultrasonic agitation DNPEP, ANPEP, UBAP2 FOLH1 764/4885ACE 88/4885MME 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.